What's New on the FDA Drugs Site
May 6, 2016
- Drug Approval Package: Cinqair (reslizumab)
- Drug Firm Annual Registration Status (updated)
- Public Notification: Step 2 contains hidden drug ingredient
- Comunicación de la FDA sobre la seguridad de los medicamentos: La FDA aprueba el cambio de nombre para el antidepresivo Brintellix (vortioxetina) para evitar la confusión con el antiplaquetario Brilinta (ticagrelor)
- FDA Drug Safety Podcast:
- FDA reminds health care professionals not to use drug products intended to be sterile from Medaus
- Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies (updated)
- National Drug Code Directory
- Wholesale Distributor and Third-Party Logistics Providers Reporting (updated)
No hay comentarios:
Publicar un comentario